GLP-1 medications can have adverse side effects if taken incorrectly, experts say
If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...
healthday1d
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
Alabama Poison Information Center warning about sickness relating to GLP-1 medications
If not administered properly, the GLP-1 medication can cause nausea, abdominal pain, and cramps, possibly leading to dehydration. The doses are normally taken a week apart, so not waiting long enough ...
Medscape1d
HFpEF and Obesity: Breakthrough Results With GLP-1 Therapies
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
U.S. News & World Report5d
Can GLP-1 Meds Harm Your Eyes?
Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...
Ad Age6d
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Are you a print subscriber? Activate your account. By Gillian Follett - 40 min 51 sec ago By Rob Mayhew - 1 hour 41 min ago 3 hours 15 min ago By Ewan Larkin - 4 hours 52 min ago By Adrianne ...
Becker's Hospital Review4d
Physicians hop on the GLP-1 train
Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.
healthday5d
Can GLP-1 Meds Harm Your Eyes?
MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye ...
pharmaphorum2d
A new GLP-1 opportunity for pharma: Supporting patients’ emotional barriers to weight loss
With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...
pharmaphorum2d
Large study points to benefits - and risks - of GLP-1 drugs
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...
Yahoo Finance4d
Global Partners LP (GLP)
Global Partners LP (NYSE:GLP) Q1 2024 Earnings Call Transcript May 8, 2024 Global Partners LP misses on earnings expectations. Reported EPS is $-0.37258 EPS, expectations were $0.1. GLP isn’t ...
Yahoo Finance5d
Global Partners LP (GLP)
PAA Plains All American Pipeline, L.P.